Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Blood (2022) 140 (Supplement 1): 9454–9456.

https://doi.org/10.1182/blood-2022-167651

Published: 2022

Journal Articles

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Andres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, Michael S. Wertheim, William J. Edenfield, Paolo Caimi, Martin Gutierrez, Luke Akard, Carolina Escobar, Justin Call, Daniel Persky, Swaminathan Iyer, Douglas J. DeMarini, Li Zhou, Xuejun Chen, Fitzroy Dawkins, Tycel J. Phillips

Blood (2019) 133 (16): 1742–1752.

https://doi.org/10.1182/blood-2018-08-867499

Published: 2019

Includes: Supplemental data

Journal Articles

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia

Christine Chen, David Siegel, Martin Gutierrez, Meagan Jacoby, Craig C. Hofmeister, Nashat Gabrail, Rachid Baz, Morten Mau-Sorensen, Jesus G. Berdeja, Michael Savona, Lynn Savoie, Suzanne Trudel, Nuchanan Areethamsirikul, T. J. Unger, Tami Rashal, Tim Hanke, Michael Kauffman, Sharon Shacham, Donna Reece

Blood (2018) 131 (8): 855–863.

https://doi.org/10.1182/blood-2017-08-797886

Published: 2018

Includes: Supplemental data

Journal Articles

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

Andres Forero-Torres, MD, Rod Ramchandren, MD, Abdulraheem Yacoub, MD, Michael S. Wertheim, MD, William J. Edenfield, MD, Paolo Caimi, MD, Martin Gutierrez, MD, Luke Akard, MD, Carolina Escobar, MD, Justin Call, MD, Daniel Persky, MD, Swami P. Iyer, MD, Douglas J. DeMarini, PhD, Li Zhou, PhD, Swamy Yeleswaram, PhD, Tycel J. Phillips, MD

Blood (2017) 130 (Supplement 1): 410.

https://doi.org/10.1182/blood.V130.Suppl_1.410.410

Published: 2017

Journal Articles

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma

Blood (2017) 129 (24): 3175–3183.

https://doi.org/10.1182/blood-2016-11-750174

Published: 2017

Includes: Supplemental data

Journal Articles

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Ramiro Garzon, Michael Savona, Rachid Baz, Michael Andreeff, Nashat Gabrail, Martin Gutierrez, Lynn Savoie, Paul Morten Mau-Sorensen, Nina Wagner-Johnston, Karen Yee, Thaddeus J. Unger, Jean-Richard Saint-Martin, Robert Carlson, Tami Rashal, Trinayan Kashyap, Boris Klebanov, Sharon Shacham, Michael Kauffman, Richard Stone

Blood (2017) 129 (24): 3165–3174.

https://doi.org/10.1182/blood-2016-11-750158

Published: 2017

Includes: Supplemental data

Journal Articles

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

Blood (2015) 126 (23): 258.

https://doi.org/10.1182/blood.V126.23.258.258

Published: 2015

Journal Articles

PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment

Philippe Armand, MD PhD, Margaret A. Shipp, MD, Vincent Ribrag, MD, Jean-Marie Michot, Pier Luigi Zinzani, MD PhD, Martin Gutierrez, MD, Ellen Snyder, PhD, Alejandro D. Ricart, MD, Arun Balakumaran, MD PhD SM, Craig H. Moskowitz, MD

Blood (2015) 126 (23): 584.

https://doi.org/10.1182/blood.V126.23.584.584

Published: 2015

Journal Articles

TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma

Owen A. O'Connor, MD, Ian W. Flinn, MD PhD, Manish R. Patel, MD, Timothy S. Fenske, MD, Changchun Deng, MD PhD, Danielle M. Brander, MD, Martin Gutierrez, MD, Suzanne Jones, PharmD, John G Kuhn, Pharm.D., Hari P. Miskin, MS, Peter Sportelli, Swaroop Vakkalanka, PhD, Howard A. Burris, III, MD

Blood (2015) 126 (23): 4154.

https://doi.org/10.1182/blood.V126.23.4154.4154

Published: 2015

Journal Articles

BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study

Jeremy S. Abramson, MD, Kristie A. Blum, MD, Ian W. Flinn, MD PhD, Martin Gutierrez, MD, Andre Goy, MD, Michael Maris, MD, Michael Cooper, MD, Michael O'Meara, MS, Darrell Borger, PhD, Jennifer Mertz, PhD, Robert J. Sims, PhD, Supko Jeffrey, PhD, Anas Younes, MD

Blood (2015) 126 (23): 1491.

https://doi.org/10.1182/blood.V126.23.1491.1491

Published: 2015

Journal Articles

Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM)

Blood (2014) 124 (21): 4773.

https://doi.org/10.1182/blood.V124.21.4773.4773

Published: 2014

Journal Articles

Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study

Philippe Armand, MD PhD, Stephen M. Ansell, MD PhD, Alexander M. Lesokhin, MD, Ahmad Halwani, MD, Michael M. Millenson, MD, Stephen J. Schuster, MD, John Timmerman, MD, Ivan Borrello, MD, Martin Gutierrez, MD, Emma C. Scott, MD, Deepika Cattry, MSc, CCRP, Bjoern Chapuy, MD PhD, Azra H. Ligon, PhD, Scott J. Rodig, MD PhD, Lili Zhu, MSc, Joseph F. Grosso, PhD, Su Young Kim, MD PhD, Margaret A. Shipp, MD

Blood (2014) 124 (21): 289.

https://doi.org/10.1182/blood.V124.21.289.289

Published: 2014

Journal Articles

PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)

Craig H. Moskowitz, MD, Vincent Ribrag, MD, Jean-Marie Michot, MD, Giovanni Martinelli, MD, Pier Luigi Zinzani, MD, PhD, Martin Gutierrez, MD, Guadalupe De Maeyer, Alexandra G. Jacob, BS, Karen Giallella, Jennifer Weimer Anderson, Martha Derosier, Joy Wang, Zijiang Yang, Eric Rubin, MD, Shelonitda Rose, Margaret A. Shipp, MD, Philippe Armand, MD PhD

Blood (2014) 124 (21): 290.

https://doi.org/10.1182/blood.V124.21.290.290

Published: 2014

Journal Articles

Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

Blood (2014) 124 (21): 291.

https://doi.org/10.1182/blood.V124.21.291.291

Published: 2014

Journal Articles

Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies

David S. Siegel, MD PhD, Andrew McDonald, MBChB, Nicolas Novitzky, MD PhD, William Bensinger, Michael Craig, MD, Frits van Rhee, MD PhD, Martin Gutierrez, MD, Edward N. Libby, MD, John Thompson, Alice S Bexon, MD, Charles Barranco, Catherine A Taylor, Richard Dondero, Leslie J. Browne, PhD, Michael R. Kurman, MD, John A. Lust, MD PhD

Blood (2014) 124 (21): 4464.

https://doi.org/10.1182/blood.V124.21.4464.4464

Published: 2014

Journal Articles

TGR-1202, a Novel Once Daily PI3Kδ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma

Howard A. Burris, MD, Manish R. Patel, MD, Danielle M. Brander, MD, Owen A. O'Connor, MD PhD, Changchun Deng, MD PhD, Timothy S. Fenske, MD, Martin Gutierrez, MD, Suzanne Jones, PharmD, John Kuhn, PharmD, Hari P. Miskin, MS, Peter Sportelli, Swaroop Vakkalanka, PhD, Ian Flinn

Blood (2014) 124 (21): 1984.

https://doi.org/10.1182/blood.V124.21.1984.1984

Published: 2014

Journal Articles

Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study

Alice S Bexon, MD, Michael Craig, MD, David S. Siegel, MD PhD, William Bensinger, Nicolas Novitzky, MD PhD, Andrew McDonald, MBChB, Martin Gutierrez, MD, Edward N. Libby, MD, Frits van Rhee, MD PhD, Jeremy Heidel, PhD, John Thompson, Charles Barranco, Catherine A Taylor, Kathleen A. Donovan, PhD, Laurie L. Moon-Tasson, BA, Leslie J. Browne, PhD, Michael R. Kurman, MD, John A. Lust, MD PhD, Richard Dondero

Blood (2014) 124 (21): 2121.

https://doi.org/10.1182/blood.V124.21.2121.2121

Published: 2014

Journal Articles

Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML)

Blood (2013) 122 (21): 1440.

https://doi.org/10.1182/blood.V122.21.1440.1440

Published: 2013

Journal Articles

Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM)

Blood (2013) 122 (21): 1942.

https://doi.org/10.1182/blood.V122.21.1942.1942

Published: 2013

Journal Articles

A Phase I Dose Escalation Study Of TGR-1202, a Novel PI3K-δ Inhibitor, For Patients With Relapsed Or Refractory Hematologic Malignancies

Michael Savona, MD, Martin Gutierrez, MD, Mark Lanasa, MD, PhD, Changchun Deng, MD, PhD, John Kuhn, PharmD, Lauren Sade, Hari Miskin, MS, Peter Sportelli, Swaroop Vakkalanka, PhD, Manish Patel, MD

Blood (2013) 122 (21): 4373.

https://doi.org/10.1182/blood.V122.21.4373.4373

Published: 2013

NARROW

Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment

TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma

BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study

Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM)

Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study

PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)

Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies

TGR-1202, a Novel Once Daily PI3Kδ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma

Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study

Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML)

Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM)

A Phase I Dose Escalation Study Of TGR-1202, a Novel PI3K-δ Inhibitor, For Patients With Relapsed Or Refractory Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only